Navigation Links
InterMune Presents Research on ITMN-191 in Hepatitis C at EASL,Annual Meeting

tors and interferons, and discovering important insights into possible treatment regimens for chronic hepatitis C," said Lawrence M. Blatt, Ph.D., Chief Scientific Officer of InterMune. "We anticipate that treatment regimens will involve multiple agents, and we are hopeful that these combinations will lead to improved, sustained virologic responses for patients who are in need of more optimal therapies."

The third presentation concerned NS3 sequence variations in HCV replicons after exposure to ITMN-191 at clinically relevant concentrations. The NS3 sequence was found to undergo dynamic changes when exposed to increasing concentrations of ITMN-191. As was seen in previous work, substitution at position 168 of NS3 appears to be fundamental to resistance but alone is not sufficient for HCV replicon persistence at all ITMN-191 concentrations achieved in the liver of animal species following oral dosing. This suggests that the genetic barrier to resistance in patients following clinical dosing of ITMN-191 may be significant dependent upon human liver exposure.

InterMune currently is conducting a Phase 1a clinical study of ITMN-191 for the treatment of chronic HCV. Preclinical toxicology and pharmacokinetic studies in multiple species demonstrated that ITMN-191 has a favorable toxicology profile, significant liver exposure, high in vitro potency and specificity, and an advantageous cross-resistance profile, including considerable effectiveness against variants of the NS3/4A protease that are resistant to other HCV protease inhibitors currently in development. The preclinical pharmacokinetic results support the exploration of twice-daily oral dosing. InterMune and Roche have a collaboration agreement for the research, development and commercialization of ITMN-191 (referred to as R7227 within the Roche research and development programs) and second-generation HCV protease inhibitor compounds.

According to the Centers for Disease Control and Prevention (
'"/>




Page: 1 2 3 4

Related medicine technology :

1. InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: InterMune Presents Research ITMN Hepatitis EASL Annual Meeting
(Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds ... its store . (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ... upgrade and policy support, China,s ... years, with total market size rising from 3.28 billion ...
(Date:1/15/2014)... As health officials across the Midwest warn against the ... Michigan will offer free diagnostic testing ... pharmacists to administer tests and, in some cases, fill the ... in the study. The Grand Rapids, ...
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... , SILVER SPRING, Md., Nov. 13 The U.S. ... acid), the first non-hormonal product cleared to treat heavy ... that helps blood to clot. , (Logo: ... is reported each year by about 3 million U.S. ...
... FRANCISCO, Nov. 13 Quantros, a leading software ... that it has partnered with Det Norske Veritas ... by the Centers for Medicare and Medicaid Services ... now integrate that company,s accreditation standards into the ...
Cached Medicine Technology:FDA Approves Lysteda to Treat Heavy Menstrual Bleeding 2Quantros Announces Partnership With Hospital Accreditation Agency DNV 2
(Date:4/24/2014)... the relevance of palliation in advanced cancer are ... trials (RCTs). This is the result of an ... Efficiency in Health Care (IQWiG), which has now ... external experts, IQWiG analysed studies on four solid ... and pancreatic cancer. For this purpose, the research ...
(Date:4/24/2014)... has been awarded one of 30 grants from the ... Academic Participating Site in its new National Clinical ... select groups of investigators charged with distributing resources in ... NCTN grant system reflects recommendations from a 2010 ... achieve four goals:, Faster design, launch, and ...
(Date:4/23/2014)... by Massachusetts General Hospital (MGH) investigators may lead to ... a serious medical problem use of fecal material ... the Clostridium difficile ( C. difficile ) ... the journal Clinical Infectious Diseases , the researchers ... donors unrelated to patients was as successful in curing ...
(Date:4/23/2014)... National Institute of Arthritis and Musculoskeletal and Skin Diseases ... Ross Prize in Molecular Medicine, conferred by the Feinstein ... award will be given on June 9 at the ... scientific presentations by Dr. O,Shea and other prominent researchers. ... , The award, which includes a $50,000 prize from ...
(Date:4/23/2014)... identified an important enzyme pathway that helps prevent new ... a condition that has been directly linked to cancer ... biochemistry, found that near the end of cell division, ... any breaks in DNA are fully repaired before the ... cells. This process helps safeguard against some of the ...
Breaking Medicine News(10 mins):Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2
... of medical miracles and the very latest in scientific ... (FBR) announced today it will distribute its free daily ... experiencing tremendous success in select markets. The Animal ... medical miracles and latest scientific breakthroughs. The host ...
... the University of Exeter reveals for the first ... physical exercise, may help reduce cigarette cravings. Published ... shows how exercise changes the way the brain ... for nicotine. For the first time, researchers used ...
... Erdman, A Cogdell Spencer,Company is pleased to ... earned the U.S. Environmental Protection Agency,s (EPA,s),prestigious ENERGY ... environmental protection. America,s commercial buildings and industrial,plants that ... facilities for energy,efficiency may qualify for the ENERGY ...
... Help Set Unprecedented NumbersVIRGINIA BEACH, Va., Feb. 10 ... able to save the lives of 406 people ... 2008.LifeNet Health saw a 13% increase from 2007 ... to hospitals and physicians. LifeNet Health provided ...
... Samples taken from the 39 hunter-killed elk during ... negative for chronic wasting disease (CWD), according to ... veterinarian. Samples also tested negative for brucellosis ... is awaiting the results of CWD testing for ...
... China Sky One,Medical, Inc. (,China Sky One Medical, ... a,leading fully integrated pharmaceutical company producing over-the-counter,drugs in ... its,revenue and net income guidance for the full-year ... to continued strong organic growth and contribution from ...
Cached Medicine News:Health News:Foundation for Biomedical Research Announces National Distribution of Daily Radio Broadcast 2Health News:First brain study reveals benefits of exercise on quitting smoking 2Health News:Erdman, A Cogdell Spencer Company Earns the ENERGY STAR(R) for Superior Energy 2Health News:Erdman, A Cogdell Spencer Company Earns the ENERGY STAR(R) for Superior Energy 3Health News:Erdman, A Cogdell Spencer Company Earns the ENERGY STAR(R) for Superior Energy 4Health News:LifeNet Health Announces a Record Year of Saving Lives and Restoring Health 2Health News:LifeNet Health Announces a Record Year of Saving Lives and Restoring Health 3Health News:Hunter-Killed Elk Test Negative for CWD and Other Diseases 2Health News:Hunter-Killed Elk Test Negative for CWD and Other Diseases 3Health News:Hunter-Killed Elk Test Negative for CWD and Other Diseases 4Health News:Hunter-Killed Elk Test Negative for CWD and Other Diseases 5Health News:China Sky One Medical, Inc. Reaffirms Guidance for 2008 Revenue and Net Income and Provides Business Update 2Health News:China Sky One Medical, Inc. Reaffirms Guidance for 2008 Revenue and Net Income and Provides Business Update 3
... part of the AXIOM family, which ... the clinical angiography, card- angiography, and ... functional and business pages you can ... delivers unrivalled value to users and ...
Spring Type with lock. Titanium....
.60 x 22mm, angled 60, .33mm end port [Simcoe]...
... The STARFlex is a fourth generation ... CardioSEAL by the addition of a unique ... coil micro-spring. The micro-spring is attached to ... and provides a self-adjusting positioning mechanism which ...
Medicine Products: